Compare CHEF & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHEF | ELVN |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.2B |
| IPO Year | 2011 | 2020 |
| Metric | CHEF | ELVN |
|---|---|---|
| Price | $107.39 | $51.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $118.33 | $74.33 |
| AVG Volume (30 Days) | 491.9K | ★ 1.5M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | 3.17 |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $1,301,520,000.00 | N/A |
| Revenue This Year | $11.03 | N/A |
| Revenue Next Year | $8.99 | N/A |
| P/E Ratio | $58.99 | ★ N/A |
| Revenue Growth | ★ 9.11 | N/A |
| 52 Week Low | $56.46 | $14.79 |
| 52 Week High | $118.51 | $62.32 |
| Indicator | CHEF | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 67.54 |
| Support Level | $106.09 | $37.77 |
| Resistance Level | $116.36 | $52.39 |
| Average True Range (ATR) | 5.21 | 2.17 |
| MACD | 0.37 | 1.29 |
| Stochastic Oscillator | 68.11 | 95.79 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States, the Middle East and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.